ChemoCentryx, Inc., announced favorable Phase I results for CCX168 at the Annual American College of Rheumatology Meeting (ACR). CCX168, the Company's orally-active small molecule antagonist, is designed to target the receptor for the pro-inflammatory protein known as 'complement 5a' (C5a), a so-called anaphylatoxin that drives inflammatory responses associated with autoimmune diseases such as vasculitis, aged-related macular degeneration, rheumatoid arthritis and related pathologies. Data from Phase I clinical trials showed that CCX168 exhibited an excellent safety profile, while producing greater than 90% receptor blockade of inflammatory cells in the blood throughout the day. Additionally, data from preclinical studies using transgenic mice (which express human C5aR) demonstrated robust efficacy of CCX168 in a vasculitis model. CCX168 is poised to enter Phase II clinical development for the treatment of patients with renal vasculitis.
These data were highlighted in poster presentations entitled:
-- "Phase 1 Clinical Safety, Pharmacokinetic and Pharmacodynamic Evaluation of the Novel C5aR antagonist CCX168, a Potential Therapeutic for ANCA-Vasculitis"
-- "The Human C5a Receptor (hC5aR) Antagonist CCX168 Effectively Ameliorates Symptoms in a Model of ANCA Glomerulonephritis (GN) in hC5aR Knock-in Mice"
"We are very pleased to report that CCX168 appears to be the first true orally-active small molecule C5aR antagonist drug ever advanced into the clinic," stated Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx. "CCX168 has the ability to safely achieve far greater than 90% receptor coverage throughout the day. While other approaches have attempted, without success, to accomplish such an attractive pharmacokinetic behavior and safety profile, CCX168 may well be in a class by itself. We think that this new agent has extraordinary potential in treating previously intractable conditions such as the devastating vasculitis seen in autoimmune diseases."
CCX168 Study Results and ANCA-Associated Vasculitis
In Phase I clinical trials CCX168 was safe and well tolerated, with excellent oral bioavailability and dose-proportional exposure increases in human subjects. Pharmacokinetic and pharmacodynamic data indicated that 30 to 50 mg of CCX168 given orally twice daily in humans results in greater than 90% C5aR coverage in blood at all times, and this is considered optimal for CCX168 evaluation in Phase II trials in vasculitis.
Supporting the Phase I data are results from a mouse model of anti-neutrophil cytoplasmic autoantibody (ANCA) associated glomerulonephritis (GN). In this study, human C5aR transgenic mice were employed, and ANCA kidney disease was profoundly inhibited by doses of CCX168 that are very similar to those achieved safely in the human Phase I studies.
CCX168 is a highly potent and very selective compound that specifically targets the receptor for the anaphylotoxin designated C5a, a component of the body's complement system and a potent driver of the inflammatory response associated with ANCA-associated vasculitis and other autoimmune disease. In ANCA disease, auto-antibodies lead to the activation and increased adhesiveness of neutrophils to endothelial cells that line the interior surfaces of blood vessels in the kidney and other organs. These adhering neutrophils accumulate inside the blood vessels and initiate an inflammatory cascade. Activation of the complement pathway occurs as a consequence, with production of C5a, one of the most potent pro-inflammatory mediators of the complement system. C5a, through binding to its receptor C5aR, induces expression of additional adhesion molecules and chemotactic factors, thus perpetually amplifying the destructive inflammatory cascade. C5aR also mediates smooth muscle contraction, increasing vascular permeability and altering blood flow. If left untreated, ANCA-associated vasculitis may lead to renal and pulmonary failure and is often fatal. Current therapies include toxic treatments such as cyclophosphamide and high dose corticosteroids. Under an alliance between ChemoCentryx and GlaxoSmithKline's (GSK's) Center of Excellence for External Drug Discovery (ceedd), GSK has the right to exercise an option to license CCX168 after Phase II clinical trials.
Certain statements in this press release may constitute "forward-looking statements". These statements are made on the basis of current expectations, forecasts and assumptions that involve risks and uncertainties, including, but not limited to, economic, competitive, governmental and technological factors outside of our control, that may cause our business, strategy or actual results to differ materially from those expressed or implied. We do not intend, and undertake no obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Source: ChemoCentryx, Inc
четверг, 30 июня 2011 г.
понедельник, 27 июня 2011 г.
Bracelets can 'ease' arthritis pain
According to a new study, magnetic bracelets can ease pain and discomfort experienced by arthritis sufferers.
UK researchers, writing in the British Medical Journal, found a significant reduction in pain scores among 65 wearers with
arthritis and claim the bracelets reduced the amount of painkillers sufferers need to take.
The study by Professor Edzard Ernst and colleagues from the Peninsular Medical School, Exeter and Plymouth, also suggested
that the stronger the bracelet the greater the effect.
The researchers claim that the one-off cost of the bracelets, at ?30 to ?50, compares well with the cost of taking
painkillers in the long term.
However, studies with dummy versions of the bracelets produced mixed results, suggesting that they might have a placebo
effect.
The authors concluded: "We cannot be certain whether our data show a specific effect of magnets, a placebo effect, or both.
Whatever the mechanism, the benefit from magnetic bracelets seems clinically useful."
hda-online.uk/html/about/phnews.asp?ItemID=7345574
UK researchers, writing in the British Medical Journal, found a significant reduction in pain scores among 65 wearers with
arthritis and claim the bracelets reduced the amount of painkillers sufferers need to take.
The study by Professor Edzard Ernst and colleagues from the Peninsular Medical School, Exeter and Plymouth, also suggested
that the stronger the bracelet the greater the effect.
The researchers claim that the one-off cost of the bracelets, at ?30 to ?50, compares well with the cost of taking
painkillers in the long term.
However, studies with dummy versions of the bracelets produced mixed results, suggesting that they might have a placebo
effect.
The authors concluded: "We cannot be certain whether our data show a specific effect of magnets, a placebo effect, or both.
Whatever the mechanism, the benefit from magnetic bracelets seems clinically useful."
hda-online.uk/html/about/phnews.asp?ItemID=7345574
пятница, 24 июня 2011 г.
Secretary Of State Backs MS Society Work Retention Project
Secretary of State for work and pensions James Purnell MP is lending his support to an MS Society-led project designed to help people with chronic and fluctuating health conditions remain in work.
Mr Purnell joins the MS Society and a range of charities, work organisations and leading UK employers and trade unions at a round table event at the Work Foundation in London today (2 June).
Also attending is Dame Carol Black, author of 'Working for a healthier tomorrow' - the influential report that prompted the DWP to support the MS Society in setting up the project: 'Work retention for people with chronic and fluctuating health conditions'.
Simon Gillespie, chief executive of the MS Society, said: "All too often, people with multiple sclerosis (MS) and other fluctuating health conditions say they left work too soon, either voluntarily or due to pressure from an employer. We want to provide an information resource that can act as a safety net at the point at which someone's working life may be about to fall off a cliff.
"We also hear positive stories from employers who have invested in keeping on an employee with a chronic or fluctuating health condition. In many cases, they have benefited from keeping experienced staff on board, and have avoided the costs of recruiting anew. This information needs to be shared and we welcome the support of the Secretary of State and Dame Carol in pushing this up the work agenda."
This working group will act as the starting point for a project supported by the DWP, designed to bring together an online resource for employees and employers, raising awareness of the support available to help people to stay in work. The site is due to be launched by the end of 2009. The conditions specifically covered by the project are MS, diabetes, rheumatoid arthritis, HIV and cancer.
Source
MS Society
Mr Purnell joins the MS Society and a range of charities, work organisations and leading UK employers and trade unions at a round table event at the Work Foundation in London today (2 June).
Also attending is Dame Carol Black, author of 'Working for a healthier tomorrow' - the influential report that prompted the DWP to support the MS Society in setting up the project: 'Work retention for people with chronic and fluctuating health conditions'.
Simon Gillespie, chief executive of the MS Society, said: "All too often, people with multiple sclerosis (MS) and other fluctuating health conditions say they left work too soon, either voluntarily or due to pressure from an employer. We want to provide an information resource that can act as a safety net at the point at which someone's working life may be about to fall off a cliff.
"We also hear positive stories from employers who have invested in keeping on an employee with a chronic or fluctuating health condition. In many cases, they have benefited from keeping experienced staff on board, and have avoided the costs of recruiting anew. This information needs to be shared and we welcome the support of the Secretary of State and Dame Carol in pushing this up the work agenda."
This working group will act as the starting point for a project supported by the DWP, designed to bring together an online resource for employees and employers, raising awareness of the support available to help people to stay in work. The site is due to be launched by the end of 2009. The conditions specifically covered by the project are MS, diabetes, rheumatoid arthritis, HIV and cancer.
Source
MS Society
вторник, 21 июня 2011 г.
Max daily OTC dose of acetaminophen shows efficacy comparable to Rx doses of naproxen for OA pain
Researchers today announced new clinical evidence showing that long-term use of maximum recommended over-the-counter (OTC) daily doses of acetaminophen (APAP) provide efficacy comparable to prescription doses of naproxen (NAP) for the management of mild-to-moderate osteoarthritis (OA) pain of the hip or knee.
Preliminary analyses of the multicenter, randomized, double-blind, parallel-group, comparative study involving 551 patients aged 40 to 75 years old with mild-to-moderate OA of the hip or knee were presented during the 2nd Joint Scientific Meeting of the American Pain Society and the Canadian Pain Society. Patients in the APAP-treated group (n=276) received 4000mg per day, while those in the NAP group (n=275) received 750 mg per day. All patients were evaluated at one-, three-, and six-month intervals for pain, stiffness, and physical function using the WOMAC™* subscale for pain.
"Even out to six months, our analyses showed no statistical differences between the efficacy of acetaminophen and naproxen for the management of osteoarthritis pain of the hip and knee," said Dr. Anthony Temple, VP Medical Affairs, McNeil Consumer & Specialty Pharmaceuticals. "These results indicate that acetaminophen is as effective as prescription doses of naproxen for the pain of arthritis when administered for up to 6 months under the care and observation of the physician."
*Western Ontario and McMaster Universities osteoarthritis index: a standard methodology to measure osteoarthritis pain relief.
About Osteoarthritis
Osteoarthritis is the most common form of arthritis in the United States, affecting more than 20 million Americans. Joint pain and stiffness due to OA results from the breakdown of cartilage in joints. The most commonly affected areas affected by OA are the fingers, knees, hips, and spine. Other joints affected less frequently include the wrists, elbows, shoulders, and ankles.
The American College of Rheumatology's "Recommendations for the Medical Management of Osteoarthritis of the Hip and Knee: 2000 Update" urge OA sufferers to begin treatment with non-medical remedies such as exercise and weight control. Acetaminophen is listed as a first-line medical treatment for osteoarthritis.
The American College of Rheumatology is an independent, professional medical and scientific society that does not guarantee, warrant or endorse any commercial product or service.
Contact: Ami Schmitz-Levine
215-273-8162
D. J. Storch & Associates Inc.
Preliminary analyses of the multicenter, randomized, double-blind, parallel-group, comparative study involving 551 patients aged 40 to 75 years old with mild-to-moderate OA of the hip or knee were presented during the 2nd Joint Scientific Meeting of the American Pain Society and the Canadian Pain Society. Patients in the APAP-treated group (n=276) received 4000mg per day, while those in the NAP group (n=275) received 750 mg per day. All patients were evaluated at one-, three-, and six-month intervals for pain, stiffness, and physical function using the WOMAC™* subscale for pain.
"Even out to six months, our analyses showed no statistical differences between the efficacy of acetaminophen and naproxen for the management of osteoarthritis pain of the hip and knee," said Dr. Anthony Temple, VP Medical Affairs, McNeil Consumer & Specialty Pharmaceuticals. "These results indicate that acetaminophen is as effective as prescription doses of naproxen for the pain of arthritis when administered for up to 6 months under the care and observation of the physician."
*Western Ontario and McMaster Universities osteoarthritis index: a standard methodology to measure osteoarthritis pain relief.
About Osteoarthritis
Osteoarthritis is the most common form of arthritis in the United States, affecting more than 20 million Americans. Joint pain and stiffness due to OA results from the breakdown of cartilage in joints. The most commonly affected areas affected by OA are the fingers, knees, hips, and spine. Other joints affected less frequently include the wrists, elbows, shoulders, and ankles.
The American College of Rheumatology's "Recommendations for the Medical Management of Osteoarthritis of the Hip and Knee: 2000 Update" urge OA sufferers to begin treatment with non-medical remedies such as exercise and weight control. Acetaminophen is listed as a first-line medical treatment for osteoarthritis.
The American College of Rheumatology is an independent, professional medical and scientific society that does not guarantee, warrant or endorse any commercial product or service.
Contact: Ami Schmitz-Levine
215-273-8162
D. J. Storch & Associates Inc.
суббота, 18 июня 2011 г.
Physical Therapy Can Help Relieve Boomers' Back Pain
Because of
increasingly demanding jobs, hectic daily schedules, participating in
recreational activities, and caring for children, grandchildren, and
elderly parents, back pain is becoming a common thread among baby boomers.
However, this generation is less resigned to simply accept the changes
brought about by aging, says the American Physical Therapy Association
(APTA).
Baby boomers, those born between 1946 and 1964 and who now make up one
fourth of the U.S. population, are leading more active lifestyles than
previous generations. "Baby boomers are as active as they were when they
were younger, but now they're living with chronic low back pain or
osteoarthritis," says Jennifer Gamboa, PT, DPT, OCS, MTC, owner of Body
Dynamics, a physical therapy private practice in Arlington, VA. "These
conditions as well as others can benefit greatly from physical therapy
intervention."
Back pain among baby boomers will be the subject of a toll-free
national hotline on Thursday, February 15, from 9:00 am until 5:00 pm,
Eastern Standard Time, sponsored by the American Physical Therapy
Association's Orthopaedic and Sports Physical Therapy Sections. Physical therapists will be
on hand to answer questions about injury prevention, exercise, and ways to
prevent back pain. The hotline is offered as a public service to help
people learn how to minimize back pain and is not a substitute for a visit
to a physical therapist or other health care professional.
"Frequently, patients may unknowingly exacerbate their pain by
exercising improperly or by having poor posture," Gamboa said. Physical
therapists can help to identify and correct those behaviors. Physical
therapists work on increasing muscle strength and cardiovascular endurance,
restoring and improving range of motion in joints, and decreasing muscle
and joint pain.
Physical therapy interventions may include therapeutic exercise, manual
therapy, and functional training, as well as exercises for strength,
flexibility, and range of motion, and devices designed to rest or support
the joint, such as orthotics or splints. "The goal of a physical therapist
is to get you back to doing what you enjoy on a daily basis with as little
discomfort as possible."
For those patients who either are just starting an exercise regime, or
for injured weekend warriors just getting back in the game, Gamboa
recommends starting off slowly and not doing too much too fast. She notes
that physical therapists devise step-wise plans in order for patients to
gain strength and mobility.
Gamboa also suggests investing in an ergonomically correct chair for
work, taking frequent breaks from computers, and participating in
stress-relieving activities, such as yoga or meditation, to offset back
pain.
Physical therapists (PTs) are health care professionals who diagnose
and treat individuals of all ages, from newborns to the elderly, who have
medical problems or other health-related conditions that limit their
abilities to move and perform functional activities in their daily lives.
PTs examine each individual and develop a plan of care using treatment
techniques to promote the ability to move, reduce pain, restore function,
and prevent disability.
The American Physical Therapy Association (apta) is a
national organization representing nearly 70,000 physical therapists,
physical therapist assistants, and students nationwide. Its goal is to
foster advancements in physical therapist education, practice, and
research. Consumers can access "Find a PT" to find a physical therapist in
their area, as well as physical therapy news and information at
apta/consumer.
American Physical Therapy Association
apta/
increasingly demanding jobs, hectic daily schedules, participating in
recreational activities, and caring for children, grandchildren, and
elderly parents, back pain is becoming a common thread among baby boomers.
However, this generation is less resigned to simply accept the changes
brought about by aging, says the American Physical Therapy Association
(APTA).
Baby boomers, those born between 1946 and 1964 and who now make up one
fourth of the U.S. population, are leading more active lifestyles than
previous generations. "Baby boomers are as active as they were when they
were younger, but now they're living with chronic low back pain or
osteoarthritis," says Jennifer Gamboa, PT, DPT, OCS, MTC, owner of Body
Dynamics, a physical therapy private practice in Arlington, VA. "These
conditions as well as others can benefit greatly from physical therapy
intervention."
Back pain among baby boomers will be the subject of a toll-free
national hotline on Thursday, February 15, from 9:00 am until 5:00 pm,
Eastern Standard Time, sponsored by the American Physical Therapy
Association's Orthopaedic and Sports Physical Therapy Sections. Physical therapists will be
on hand to answer questions about injury prevention, exercise, and ways to
prevent back pain. The hotline is offered as a public service to help
people learn how to minimize back pain and is not a substitute for a visit
to a physical therapist or other health care professional.
"Frequently, patients may unknowingly exacerbate their pain by
exercising improperly or by having poor posture," Gamboa said. Physical
therapists can help to identify and correct those behaviors. Physical
therapists work on increasing muscle strength and cardiovascular endurance,
restoring and improving range of motion in joints, and decreasing muscle
and joint pain.
Physical therapy interventions may include therapeutic exercise, manual
therapy, and functional training, as well as exercises for strength,
flexibility, and range of motion, and devices designed to rest or support
the joint, such as orthotics or splints. "The goal of a physical therapist
is to get you back to doing what you enjoy on a daily basis with as little
discomfort as possible."
For those patients who either are just starting an exercise regime, or
for injured weekend warriors just getting back in the game, Gamboa
recommends starting off slowly and not doing too much too fast. She notes
that physical therapists devise step-wise plans in order for patients to
gain strength and mobility.
Gamboa also suggests investing in an ergonomically correct chair for
work, taking frequent breaks from computers, and participating in
stress-relieving activities, such as yoga or meditation, to offset back
pain.
Physical therapists (PTs) are health care professionals who diagnose
and treat individuals of all ages, from newborns to the elderly, who have
medical problems or other health-related conditions that limit their
abilities to move and perform functional activities in their daily lives.
PTs examine each individual and develop a plan of care using treatment
techniques to promote the ability to move, reduce pain, restore function,
and prevent disability.
The American Physical Therapy Association (apta) is a
national organization representing nearly 70,000 physical therapists,
physical therapist assistants, and students nationwide. Its goal is to
foster advancements in physical therapist education, practice, and
research. Consumers can access "Find a PT" to find a physical therapist in
their area, as well as physical therapy news and information at
apta/consumer.
American Physical Therapy Association
apta/
среда, 15 июня 2011 г.
Can-Fite Completed Patient Enrollment For The Confirmatory Phase IIb Trial In Rheumatoid Arthritis Patients With CF101
Can-Fite BioPharma (TASE:CFBI), a biotechnology company traded on the Tel Aviv Stock Exchange has achieved yet another goal by completion of enrollment of 230 patients in its confirmatory phase IIb RA trial. Approximately 230 patients were enrolled to this study, randomized into 3 groups treated with 0.1 mg and 4 mg of CF101, and placebo. Patients are taking the drug for 12 weeks plus 2 weeks of follow-up. The trial is being conducted in 30 sites in Europe and Israel. The company estimates to release study data on H1 2009.
In addition, the company recently announced that it has signed an out license agreement with Kwang Dong Pharmaceutical Co., a Korean company, granting Kwang Dong exclusive rights to develop and commercialize the drug CF101 for rheumatoid arthritis, in Korea. CF101, Can-Fite's lead drug, is currently being tested in a multi-national Phase IIb study for its therapeutic activity in the treatment of rheumatoid arthritis and in two Phase IIa studies: one for the treatment of psoriasis and the other for dry eye syndrome.
The terms of the license include an upfront payment as well as milestone payments to Can-Fite in an aggregate amount of US$ 1.5M; and certain royalties on sales. Additionally, Kwang Dong will also purchase equity in Can-Fite in an amount representing 1% of Can-Fite's outstanding share capital at a premium of 50% above market price.
CAN-FITE BIOPHARMA LTD is a public company traded on the Tel Aviv Stock Exchange. The Company, which commenced business activity in 2000, was founded by Prof. Pnina Fishman, an investigator from Rabin Medical Center, and patent attorney Dr. Ilan Cohn, a senior associate at Reinhold Cohn Patent Attorneys. Prof. Pnina Fishman serves as the CEO of Can-Fite. The Company was founded on the basis of scientific findings made by Prof. Pnina Fishman and focuses on the development of molecule-based drugs that bind to receptors of cancerous or inflammatory cells and inhibit their development.
Can-Fite's development pipeline currently has two drugs: CF101 and CF102. The company is simultaneously conducting several preclinical and clinical trials with the two drugs for various indications. CF101 is being studied for the treatment of rheumatoid arthritis (Phase IIb), dry eye syndrome (Phase II) and psoriasis (Phase II). Can-Fite develops CF102 for the treatment of liver conditions, including liver cancer, hepatitis infections and liver tissue regeneration.
Source
Can-Fite BioPharma
Pnina Fishman, Ph.D.
Chief Executive Officer
canfite
In addition, the company recently announced that it has signed an out license agreement with Kwang Dong Pharmaceutical Co., a Korean company, granting Kwang Dong exclusive rights to develop and commercialize the drug CF101 for rheumatoid arthritis, in Korea. CF101, Can-Fite's lead drug, is currently being tested in a multi-national Phase IIb study for its therapeutic activity in the treatment of rheumatoid arthritis and in two Phase IIa studies: one for the treatment of psoriasis and the other for dry eye syndrome.
The terms of the license include an upfront payment as well as milestone payments to Can-Fite in an aggregate amount of US$ 1.5M; and certain royalties on sales. Additionally, Kwang Dong will also purchase equity in Can-Fite in an amount representing 1% of Can-Fite's outstanding share capital at a premium of 50% above market price.
CAN-FITE BIOPHARMA LTD is a public company traded on the Tel Aviv Stock Exchange. The Company, which commenced business activity in 2000, was founded by Prof. Pnina Fishman, an investigator from Rabin Medical Center, and patent attorney Dr. Ilan Cohn, a senior associate at Reinhold Cohn Patent Attorneys. Prof. Pnina Fishman serves as the CEO of Can-Fite. The Company was founded on the basis of scientific findings made by Prof. Pnina Fishman and focuses on the development of molecule-based drugs that bind to receptors of cancerous or inflammatory cells and inhibit their development.
Can-Fite's development pipeline currently has two drugs: CF101 and CF102. The company is simultaneously conducting several preclinical and clinical trials with the two drugs for various indications. CF101 is being studied for the treatment of rheumatoid arthritis (Phase IIb), dry eye syndrome (Phase II) and psoriasis (Phase II). Can-Fite develops CF102 for the treatment of liver conditions, including liver cancer, hepatitis infections and liver tissue regeneration.
Source
Can-Fite BioPharma
Pnina Fishman, Ph.D.
Chief Executive Officer
canfite
воскресенье, 12 июня 2011 г.
9.5% Of American Adults Treated For Arthritis
Approximately 21 million Americans - 9.5 percent of adults 18 and older - either visited or called a doctor for a prescription to reduce arthritis pain in 2005, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.
The most common form of arthritis is osteoarthritis. It is usually associated with aging and most often causes pain and stiffness in the fingers, knees, and hips. A less common form of arthritis is rheumatoid arthritis, occurring when the body's own defense system doesn't work properly, causing pain in the joints and bones. Rheumatoid arthritis may also affect internal organs and systems.
AHRQ's data found that in 2005:
-- Some 9.5 million adults sought treatment, but women did it more often than men - 12 percent vs.7 percent.
-- More whites sought treatment for arthritis (10.5 percent), followed closely by blacks (just under 10 percent), compared to Hispanics (6 percent), and Asians (4 percent).
-- About $32 billion was spent for arthritis treatments, which included doctor visits (36 percent), hospital care (31 percent), prescription drugs (21 percent), home health care (12 percent) and emergency room visits (less than 1 percent).
AHRQ, which is part of the U.S. Department of Health and Human Services, works to enhance the quality, safety, efficiency, and effectiveness of health care in the United States. The data in this AHRQ News and Numbers summary are taken from the Medical Expenditure Panel Survey, a detailed source of information on the health services used by Americans, the frequency with which they are used, the cost of those services, and how they are paid. For more information, go to Arthritis: Use and Expenditures among U.S. Noninstitutionalized Population, 2005.
ahrq
The most common form of arthritis is osteoarthritis. It is usually associated with aging and most often causes pain and stiffness in the fingers, knees, and hips. A less common form of arthritis is rheumatoid arthritis, occurring when the body's own defense system doesn't work properly, causing pain in the joints and bones. Rheumatoid arthritis may also affect internal organs and systems.
AHRQ's data found that in 2005:
-- Some 9.5 million adults sought treatment, but women did it more often than men - 12 percent vs.7 percent.
-- More whites sought treatment for arthritis (10.5 percent), followed closely by blacks (just under 10 percent), compared to Hispanics (6 percent), and Asians (4 percent).
-- About $32 billion was spent for arthritis treatments, which included doctor visits (36 percent), hospital care (31 percent), prescription drugs (21 percent), home health care (12 percent) and emergency room visits (less than 1 percent).
AHRQ, which is part of the U.S. Department of Health and Human Services, works to enhance the quality, safety, efficiency, and effectiveness of health care in the United States. The data in this AHRQ News and Numbers summary are taken from the Medical Expenditure Panel Survey, a detailed source of information on the health services used by Americans, the frequency with which they are used, the cost of those services, and how they are paid. For more information, go to Arthritis: Use and Expenditures among U.S. Noninstitutionalized Population, 2005.
ahrq
Подписаться на:
Сообщения (Atom)